<DOC>
	<DOCNO>NCT01637636</DOCNO>
	<brief_summary>The purpose research study understand whether difference amount tasimelteon ( include breakdown product ) blood take alone combination either rifampin ketoconazole . Cytochrome P450 3A4 important enzyme produce body breakdown certain medication . In study , effect important enzyme tasimelteon study assess effect rifampin ketoconazole tasimelteon break body . Rifampin known inducer Cytochrome P450 3A4 enzyme meaning increase activity enzyme . Ketoconazole known inhibitor Cytochrome P450 3A4 enzyme meaning decrease activity enzyme . In addition , safety tolerability tasimelteon also assess throughout study .</brief_summary>
	<brief_title>Pharmacokinetics Tasimelteon Alone Combination With CYP3A4 Inhibitor , Ketoconazole , CYP3A4 Inducer , Rifampin .</brief_title>
	<detailed_description />
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inducers</mesh_term>
	<criteria>1 . Men woman age 18 55 year , inclusive ; 2 . Nonsmokers ; 3 . Subjects Body Mass Index ( BMI ) ≥18 ≤35 kg/m^2 ; 4 . Males , nonfecund female , female childbearing potential use acceptable method birth control period 35 day first dose ; 5 . Vital sign within range show : 1 . Body temperature 35.037.5 °C ; 2 . Systolic blood pressure 90150 mmHg ; 3 . Diastolic blood pressure 5095 mmHg ; 4 . Pulse rate 50100 bpm . 6 . Ability acceptance provide write informed consent ; 7 . Willing able comply study requirement restriction ; 8 . In good health determine past medical history , physical examination , electrocardiogram , clinical laboratory test urinalysis ; 1 . History recent ( within six month ) drug alcohol abuse ; 2 . Any major surgery within three month Baseline minor surgery within one month ; 3 . History current evidence cardiovascular , hepatic , hematopoietic , renal , gastrointestinal metabolic dysfunction psychiatric disease judge Investigator clinically significant ; 4 . History ( include family history ) current evidence congenital long QT syndrome know acquire QT interval prolongation ; 5 . Subjects currently consider suicide risk , subject ever make suicide attempt , currently demonstrate active ( within past 6 month ) suicidal ideation ; 6 . Any condition require regular use medication except listed Section 8.2 protocol ; 7 . Exposure investigational drug , include placebo , within 30 day 5 halflives ( whichever longer ) baseline 8 . Exposure ( within 2 week Baseline Visit ) overthecounter medication include melatonin , dietary supplement and/or herbal remedy , except list Section 8.2 ; 9 . Treatment drug know cause major organ system toxicity ( e.g. , chloramphenicol tamoxifen ) 60 day precede Screening visit ; 10 . History intolerance and/or hypersensitivity ketaconazole , drug similar ketoconazole ( e.g . miconzaole fluconazole ) , rifampin , tasimelteon , and/or drug similar tasimelteon include melatonin ; 11 . Donation loss 400 mL blood within one month prior Baseline Visit ; 12 . Significant illness within two week prior Baseline ; 13 . Pregnant lactating female ; 14 . History porphyria liver disease and/or positive one follow serological result : 1 . A positive hepatitis C antibody test ( antiHCV ) 2 . A positive hepatitis B surface antigen ( HBsAg ) 3 . A positive HIV test result 15 . Participation previous BMS214778/VEC162 trial ; 16 . Use food beverage contain grapefruit grapefruit juice , apple orange juice , vegetables mustard green family ( e.g . kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard green ) charbroiled meat least 2 week Baseline Visit end study ; 17 . Inability venipunctured and/or tolerate venous access ; 18 . Subjects unable read speak English ; 19 . Any sound medical reason determine clinical Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>rifampin ,</keyword>
	<keyword>ketoconazole ,</keyword>
	<keyword>CYP3A4 ,</keyword>
	<keyword>tasimelteon ,</keyword>
	<keyword>VEC-162</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>